Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Multicentre, Double-blind, Placebo-controlled, Crossover Trial Determining the Efficacy of Dry Powder Mannitol in Improving Lung Function in Subjects With Cystic Fibrosis Aged Six to Seventeen Years

Next Previous
Trial Profile

A Randomised, Multicentre, Double-blind, Placebo-controlled, Crossover Trial Determining the Efficacy of Dry Powder Mannitol in Improving Lung Function in Subjects With Cystic Fibrosis Aged Six to Seventeen Years

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mannitol (Primary)
  • Indications Cystic fibrosis
  • Focus Registrational; Therapeutic Use
  • Sponsors Pharmaxis; Syntara Limited

Most Recent Events

  • 04 Dec 2023 According to a Syntara Limited media release, Pharmaxis has changed its name to Syntara Limited
  • 16 Dec 2015 Primary endpoint (Effect on lung function (FEV1)) has been met, according to a Pharmaxis media release.
  • 16 Dec 2015 According to a Pharmaxis media release, this trial was designed in consultation with the EMEA as a condition of the marketing authorisation granted for Bronchitol for treating adult cystic fibrosis patients in Europe. Based on the positive trial results Pharmaxis will consider an application to extend the European Union marketing authorisation to include children and adolescents in the indication.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top